Should I buy or sell Phreesia stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHR shares. View PHR analyst ratings or view top-rated stocks .

What is Phreesia's stock price target for 2024?

14 brokerages have issued 12 month price objectives for Phreesia's stock. Their PHR share price targets range from $23.00 to $40.00. On average, they predict the company's stock price to reach $31.62 in the next twelve months. This suggests a possible upside of 36.5% from the stock's current price. View analysts price targets for PHR or view top-rated stocks among Wall Street analysts .

How have PHR shares performed in 2024?

Phreesia's stock was trading at $23.15 on January 1st, 2024. Since then, PHR shares have increased by 0.0% and is now trading at $23.16. View the best growth stocks for 2024 here .

When is Phreesia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024. View our PHR earnings forecast .

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) posted its earnings results on Thursday, March, 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. The company had revenue of $95 million for the quarter, compared to analysts' expectations of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative trailing twelve-month return on equity of 53.33%. The company's quarterly revenue was up 24.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.72) EPS.

What ETFs hold Phreesia's stock?

ETFs with the largest weight of Phreesia (NYSE:PHR) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC) , Fidelity Digital Health ETF (FDHT) , Fidelity Disruptive Medicine ETF (FMED) and Jacob Forward ETF (JFWD) . iShares U.S. Healthcare Providers ETF (IHF) .

What guidance has Phreesia issued on next quarter's earnings?

Phreesia issued an update on its FY 2025 earnings guidance on Thursday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $424.0 million-$434.0 million, compared to the consensus revenue estimate of $428.1 million.

What is Chaim Indig's approval rating as Phreesia's CEO?

172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com . Chaim Indig has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY) , Zscaler (ZS) , Okta (OKTA) , DocuSign (DOCU) , HealthEquity (HQY) , Block (SQ) , Appian (APPN) , Walt Disney (DIS) , Globant (GLOB) and Invitae (NVTA) .

When did Phreesia IPO?

Phreesia (PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray acted as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Phreesia's stock is owned by a number of institutional and retail investors. Top institutional investors include Moody National Bank Trust Division (0.13%) and WoodTrust Financial Corp (0.05%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman , Amy Beth Vanduyn , Balaji Gandhi, Chaim Indig , David Linetsky , Edward L Cahill , Evan Roberts , Gillian Munson , Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub and Randy Rasmussen . View institutional ownership trends .

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NYSE:PHR

Phreesia (PHR) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free PHR Stock Alerts

$23.16

+0.16 (+0.70%)

(As of 04/17/2024 ET)

Compare

Today's Range: $23.00
▼
$23.51
50-Day Range: $21.78
▼
$28.87
52-Week Range: $12.05
▼
$34.98

Volume: 383,738 shs
Average Volume: 522,719 shs
Market Capitalization: $1.31 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.62

Get Phreesia alerts:

Phreesia MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 36.5% Upside
$31.62 Price Target
Short Interest: Healthy
3.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.60
Upright™ Environmental Score
News Sentiment: -0.14
Based on 22 Articles This Week
Insider Trading: Selling Shares
$1.88 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.48) to ($1.08) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

111th out of 914 stocks

Business Services, Not Elsewhere Classified Industry

20th out of 86 stocks

4.4

Analyst's Opinion

Consensus Rating
Phreesia has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Phreesia has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
3.83% of the outstanding shares of Phreesia have been sold short.
Short Interest Ratio / Days to Cover
Phreesia has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Phreesia has recently decreased by 3.57%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Phreesia does not currently pay a dividend.
Dividend Growth
Phreesia does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Phreesia has received a 60.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Patient flow management systems", "Health care management software", and "Personal health record software" products. See details.
Environmental Sustainability
The Environmental Impact score for Phreesia is -0.60.

1.0

News and Social Media Coverage

News Sentiment
Phreesia has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 22 news articles for Phreesia this week, compared to 4 articles on an average week.
Search Interest
Only 2 people have searched for PHR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Phreesia to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,884,749.00 in company stock.
Percentage Held by Insiders
Only 5.80% of the stock of Phreesia is held by insiders.
Percentage Held by Institutions
92.10% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Phreesia are expected to grow in the coming year, from ($1.48) to ($1.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phreesia is -9.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phreesia is -9.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Phreesia has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Phreesia Stock (NYSE:PHR)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

PHR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHR Stock News Headlines

April 13, 2024 | insidertrades.com

Janet Gunzburg Sells 2,768 Shares of Phreesia, Inc. (NYSE:PHR) Stock

April 11, 2024 | insidertrades.com

Phreesia, Inc. (NYSE:PHR) Insider Sells $38,657.58 in Stock

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 11, 2024 | insidertrades.com

Janet Gunzburg Sells 2,817 Shares of Phreesia, Inc. (NYSE:PHR) Stock

March 28, 2024 | insidertrades.com

Phreesia, Inc. (NYSE:PHR) CFO Sells $81,327.84 in Stock

March 26, 2024 | insidertrades.com

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts Sells 25,962 Shares

April 16, 2024 | americanbankingnews.com

Phreesia, Inc. (NYSE:PHR) Given Average Recommendation of "Moderate Buy" by Brokerages

April 14, 2024 | americanbankingnews.com

Insider Selling: Phreesia, Inc. (NYSE:PHR) Insider Sells 2,768 Shares of Stock

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 12, 2024 | investing.com

Phreesia Inc. general counsel sells over $233k in company stock

April 12, 2024 | investing.com

Phreesia executive sells over $164,000 in company stock